• Eric A Goethe, Michael Youssef, Akash J Patel, Ali Jalali, J Clay Goodman, and Jacob J Mandel.
• Department of Neurology, Baylor College of Medicine, Houston, Texas, USA.
• World Neurosurg. 2019 Aug 1; 128: 127-130.

BackgroundPapillary glioneuronal tumors (PGNTs) are rare World Health Organization grade I neoplasms that are characterized by a benign course and excellent response to surgical resection. A few reports exist of tumors with more aggressive clinical and histologic features. In this report we detail the case of an unusually aggressive PGNT in a 67-year-old woman.Case DescriptionThe patient had a 3-year history of seizures and was diagnosed with a frontoparietal mass on imaging. She underwent subtotal resection with a histologic diagnosis of PGNT. Less than a year after surgery, the patient experienced recurrence of disease and underwent reresection and adjuvant radiation treatment. The patient's disease continued to progress despite radiation treatment, so adjuvant temozolomide was initiated. Molecular testing was performed and revealed a TERT promotor mutation, an FGFR3-TACC3 oncogenic fusion, and a copy number loss in CDKN2A/CDKN2B.ConclusionsPGNTs, while typically benign, can rarely recur after surgery. Molecular testing should be performed on all PGNTs to help possibly identify more aggressive tumors and potentially reveal novel treatment options.Copyright © 2019 Elsevier Inc. All rights reserved.

43 keywords...

hide…